Table 3 Trials of bevacizumab in early-stage breast cancer: preoperative therapy
Reference | Phase | Number of patients | Treatment | Response rate (%) |
|---|---|---|---|---|
Hurvitz et al. [30] | II (randomised) | 37 of 90 planned (HER2-negative) | A: TAC + B (7.5 mg/kg) | All regimens: RR 95; CR 59; PR 35 |
| Â | Â | Â | B: TAC + placebo | A: PR 58; CR 42 |
| Â | Â | Â | C: TAC + B (15 mg/kg) | B + D: PR 27; CR 64 |
| Â | Â | Â | D: TAC + placebo (2:1:2:1, randomisation) | D: PR 21; CR 71 |
Makhoul et al. [31] | II | 36 (11 HER2-negative) | Bevacizumab + docetaxel + cyclophosphamide (4 cycles) → doxorubicin (4 cycles) → bevacizumab (adjuvant, 9 cycles) | PR 31; CR 39; pCR breast 38; pCR breast + axilla 29 |
Greil et al. [32] | II | 18 (HER2-negative) | Bevacizumab × 5* + (docetaxel + capecitabine) × 6* | pCR 22 |
Balduzzi et al. [33] | II | 30 | Epirubicin + cisplatin + fluorouracil × 4* → bevacizumab + paclitaxel × 3* | pCR 33; CR + PR 87 |
Wedam et al. [34] | II | 21 (81% HER2-negative) | Bevacizumab × 1* → bevacizumab + doxorubicin + docetaxel × 6* | PR 67; CR 0 |
Lyons et al. [35] | II | 49 (number of patients receiving bevacizumab not reported) | Docetaxel + bevacizumab or docetaxel | CR 14; PR 65 |
Raefsky et al. [36] | II | 25 | Nab-paclitaxel + carboplatin × 6* + trastuzumab + bevacizumab × 23* | pCR 26; PR 16 |
Locatelli et al. [37] | II (randomised) | 23 (19 evaluable; locally advanced) | B → vinorelbine + capecitabine (9 pts) | NR |
| Â | Â | Â | B + vinorelbine + capecitabine (14 pts) | NR |
Torrisi et al. [38] | II | 37 (36 evaluable; estrogen and/or progesterone positive) | Bevacizumab + capecitabine + vinorelbine + letrozole | RR 86; pCR 0 |